Grimshaw W T, Colman P J, Weatherley A J
Pfizer Central Research, Sandwich, Kent.
Vet Rec. 1987 Oct 24;121(17):393-6. doi: 10.1136/vr.121.17.393.
Sulbactam-ampicillin is a combination of sulbactam, a beta-lactamase inhibitor, and ampicillin, a broad spectrum beta-lactam antibiotic. The efficacy of sulbactam-ampicillin was evaluated in the treatment of calf respiratory disease associated with ampicillin-sensitive and ampicillin-resistant strains of Pasteurella haemolytica and Pasteurella multocida. Treatment with sulbactam-ampicillin was compared with treatment with ampicillin alone in 123 Friesian calves, between three and five weeks old, exhibiting clinical signs of respiratory disease. Seven of the 59 calves treated with ampicillin died whereas only one death occurred in the 64 calves treated with sulbactam-ampicillin. In the calves which survived, treatment with sulbactam-ampicillin resulted in a significantly better clinical response, as measured by the reduction in severity of clinical signs. The results of bacteriological examinations indicated that there was a marked increase in the proportion of ampicillin-resistant isolates of P haemolytica subsequent to treatment with ampicillin, whereas the proportion of ampicillin-resistant isolates of P. haemolytica recovered from calves treated with sulbactam-ampicillin had declined. The superior efficacy of sulbactam-ampicillin observed in this study is explained by the inhibitory effect of sulbactam on beta-lactamases produced by resistant bacteria, thus rendering them susceptible to the ampicillin.
舒巴坦-氨苄西林是一种β-内酰胺酶抑制剂舒巴坦与广谱β-内酰胺抗生素氨苄西林的组合。对舒巴坦-氨苄西林治疗与溶血性巴氏杆菌和多杀性巴氏杆菌的氨苄西林敏感及耐药菌株相关的犊牛呼吸道疾病的疗效进行了评估。在123头3至5周龄出现呼吸道疾病临床症状的弗里斯兰犊牛中，将舒巴坦-氨苄西林治疗与单独使用氨苄西林治疗进行了比较。接受氨苄西林治疗的59头犊牛中有7头死亡，而接受舒巴坦-氨苄西林治疗的64头犊牛中仅1头死亡。在存活的犊牛中，以临床症状严重程度的降低来衡量，舒巴坦-氨苄西林治疗产生了显著更好的临床反应。细菌学检查结果表明，用氨苄西林治疗后，溶血性巴氏杆菌氨苄西林耐药分离株的比例显著增加，而从接受舒巴坦-氨苄西林治疗的犊牛中回收的溶血性巴氏杆菌氨苄西林耐药分离株的比例有所下降。本研究中观察到的舒巴坦-氨苄西林的卓越疗效可通过舒巴坦对耐药菌产生的β-内酰胺酶的抑制作用来解释，从而使它们对氨苄西林敏感。
